Aldesleukin

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameAldesleukin
Drug Alias NameChiron IL-2 (Chiron)阿地白介素MacrolinIL-2-ChironInterleukin-2-Chiron +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunostimulantsInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsUveal melanomaSkin MelanomaCNS Embryonal Tumor +[58] 
Global Approved IndicationsCarcinoma, Renal CellMelanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date1992/01/29
Country/TerritoryBelgiumCanadaUnited States +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesChiron Spa
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteChironNational Institutes Of Health +[8] 
Inactive CompaniesUtah State UniversityChiron CoNational Institute For Health Research, United Kingdom +[31] 
Active IndicationsSkin MelanomaGraft vs Host DiseaseDiabetes Mellitus, Type 1 +[12] 
Inactive IndicationsUveal melanomaCNS Embryonal TumorSolid tumours +[46] 

Other Information

ATC CodeL03AC01
Related LinksDrugBankKEGG